Promed Bioscience Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $789K

  • Investors
  • 2

Promed Bioscience General Information

Description

Operator of a biotech company intended to address emergent needs in the research and medical fields. The company produces purified medical-grade atelocollagen from animal tissue and distributes it internationally for a wide range of research, clinical and cosmeceutical applications that help create gels for cell culture, scaffolds for tissue engineering and assays that study cell behavior and cellular interactions with the extracellular environment, enabling medical professionals and researchers to combat the breakdown and loss of connective tissue from daily wear and tear, injury or disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Alkidamou Street
  • 4101 Agios Athanasios
  • Limassol, 4101
  • Cyprus
+357
Primary Industry
Biotechnology
Other Industries
Other Commercial Products
Vertical(s)
Corporate Office
  • 1 Alkidamou Street
  • 4101 Agios Athanasios
  • Limassol, 4101
  • Cyprus
+357

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Promed Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 10-Nov-2022 $789K Completed Generating Revenue
1. Early Stage VC 18-Jun-2020 Completed Generating Revenue
To view Promed Bioscience’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Promed Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Promed Bioscience Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
ASBISC Corporate Venture Capital Corporate Venture Capital
Kinisis Ventures Venture Capital Minority
To view Promed Bioscience’s complete investors history, request access »

Promed Bioscience FAQs

  • When was Promed Bioscience founded?

    Promed Bioscience was founded in 2017.

  • Where is Promed Bioscience headquartered?

    Promed Bioscience is headquartered in Limassol, Cyprus.

  • What is the size of Promed Bioscience?

    Promed Bioscience has 8 total employees.

  • What industry is Promed Bioscience in?

    Promed Bioscience’s primary industry is Biotechnology.

  • Is Promed Bioscience a private or public company?

    Promed Bioscience is a Private company.

  • What is the current valuation of Promed Bioscience?

    The current valuation of Promed Bioscience is .

  • What is Promed Bioscience’s current revenue?

    The current revenue for Promed Bioscience is .

  • How much funding has Promed Bioscience raised over time?

    Promed Bioscience has raised $2.18M.

  • Who are Promed Bioscience’s investors?

    ASBISC Corporate Venture Capital and Kinisis Ventures have invested in Promed Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process